Medicis Announces First Quarter Fiscal 2001 Conference Call and Webcast

SCOTTSDALE, Ariz.--Oct. 18, 2000--Medicis Pharmaceutical Corporation (NYSE:MRX) today announced it will report first quarter fiscal 2001 financial results after the market closes on Thursday, October 19, 2000.

The Company will host a conference call at 5:15 p.m. Eastern Time (2:15 p.m. Pacific Time) to review the September 30, 2000 first quarter financial results, as well as provide an update on other business matters of the Company. A live webcast will also be available at http://www.streetevents.com.

Interested participants should contact Medicis Investor Relations to reserve a line on the call. Callers should dial in approximately 10 minutes prior to the start of the call.

The phone number to join the conference call is 913-981-5581 for both domestic and international callers. No access code is necessary for the live call. For investors unable to participate in the live call, a replay will be available soon after the live call. The phone number to access the replay is 719-457-0820 and the access code is 567883.

NOTE: Please contact Medicis Investor Relations Thursday before 3 p.m. Eastern Time (Noon Pacific Time) at (602) 808-3854 or investor_relations@medicis.com to RSVP and guarantee a space on the call. A certain number of lines will be reserved based upon registrations.

Medicis is the leading independent pharmaceutical company in the United States focusing primarily on the treatment of dermatological conditions. Medicis develops and markets leading products for major segments within dermatology including acne, fungal infections, psoriasis, eczema, rosacea, seborrheic dermatitis, head lice and cosmesis (improvement in the texture and appearance of skin). Primary products include the prescription brands DYNACIN(R) (minocycline HCl), TRIAZ(R) (benzoyl peroxide), LUSTRA(R) (hydroquinone), LOPROX(R) (ciclopirox), OVIDE(R) (malathion), PLEXION(TM) (sodium sulfacetamide/sulfur), LIDEX(R) (fluocinonide), SYNALAR(R) (fluocinolone acetonide), TOPICORT(R) (desoximetasone), NOVACET(R) (sodium sulfacetamide/sulfur) and A/T/S(R) (erythromycin); the over-the-counter brand ESOTERICA(R); and BUPHENYL(TM) (sodium phenylbutyrate), a prescription product indicated in the treatment of Urea Cycle Disorder.

Except for historical information, this news release contains certain forward-looking statements that involve risks and uncertainties which may cause actual results to differ materially from the statements made, including the Company's dependence on sales of key products, uncertainty of future financial results and fluctuations in operating results, dependence on the Company's acquisition strategy, new product introductions and other risks described from time to time in the Company's SEC filings. These forward-looking statements represent the judgment of the Company, as of the date of this release, and Medicis disclaims any intent or obligation to update these forward-looking statements.

NOTE: Full prescribing information for any Medicis prescription product is available by contacting the Company.

Contacts:
Medicis Pharmaceutical Corporation
Libby Ivy, 602/808-3854
All trademarks are the property of their respective owners.